Skip to main content
. Author manuscript; available in PMC: 2015 Oct 29.
Published in final edited form as: Cell. 2014 May 8;157(4):882–896. doi: 10.1016/j.cell.2014.03.026

Figure 6. NAD+ augmentation rescues the mitochondrial and aging phenotype in XPA− cells and xpa-1 worms.

Figure 6

(A) Immunoblot of XPA− and XPA+ cells treated for 24 h with the NAD+ precursors nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) or the PARP inhibitor AZD2281. (B) Mitochondrial parameters of XPA− and XPA+ cells treated for 24 hours with NR, NMN, AZD2281 or DPQ (means ± S.E.M., n=3). (C) NAD+ levels of XPA− and XPA+ cells treated for 24 hours with NR, NMN or AZD2281 (means ± S.E.M., n=3). (D) NAD+ levels of WT (N2) or xpa-1 mutant worms treated with NR or NMN throughout their lifespan (means ± S.E.M., n=3). (E) Immunoblot of WT (N2) or xpa-1 mutants treated with NR or NMN throughout their lifespan. (F-K) Lifespan curves of WT (N2) or xpa-1 mutants treated with NR, NMN or AZD2281 throughout their lifespan (Kaplan Meyer survival curves were calculated from populations of 199 to 491 animals in each group, significance was calculated by the log-rank test).